Get the Stockscreener App
11.50
3.60%
0.40
Transcode Therapeutics Inc stock is traded at $11.50, with a volume of 36,602.
It is up +3.60% in the last 24 hours and up +53.33% over the past month.
TransCode Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing innovative drugs and diagnostics for treating and identifying cancer. TransCode recently commenced its first clinical trial. The Company's lead therapeutic candidate, TTX-MC138, comprises an oligonucleotide conjugated to an iron oxide nanoparticle designed to be administered by infusion to inhibit the ability of metastatic tumor cells to survive. The goal of the therapy, if approved, is to achieve durable disease regression and long-term patient survival.
See More
Previous Close:
$11.10
Open:
$10.8
24h Volume:
36,602
Relative Volume:
0.28
Market Cap:
$9.59M
Revenue:
-
Net Income/Loss:
$-14.93M
P/E Ratio:
-0.0432
EPS:
-266.137
Net Cash Flow:
$-15.87M
1W Performance:
-2.04%
1M Performance:
+53.33%
6M Performance:
-94.57%
1Y Performance:
-95.49%
1-Day Range:
$10.17
$12.22
1-Week Range:
$10.17
$15.88
52-Week Range:
$6.1478
$739.20
Transcode Therapeutics Inc Stock (RNAZ) Company Profile
Name
Transcode Therapeutics Inc
Sector
Industry
Phone
857-301-6857
Address
6 LIBERTY SQUARE, BOSTON
Compare RNAZ with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RNAZ
Transcode Therapeutics Inc
|
11.50 | 9.25M | 0 | -14.93M | -15.87M | -266.14 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Transcode Therapeutics Inc Stock (RNAZ) Latest News
Analyzing recovery setups for TransCode Therapeutics Inc. investorsFree Trade Setups With AI Powered Filters - Newser
Using RSI to spot recovery in TransCode Therapeutics Inc.Short-Term Swing Opportunity Summary Sheet - Newser
Top Risks to Consider Before Buying TransCode Therapeutics Inc. StockWeekly Trend Screener with Momentum Picks - Newser
Will breakout in TransCode Therapeutics Inc. lead to full recoveryFree Trend Following Strategy With Stop Loss - Newser
TransCode Therapeutics Inc. Company’s Quarterly Earnings Growth: What the Numbers SayEntry Optimization Tool with Screener Logic - Newser
Signal strength of TransCode Therapeutics Inc. stock in tech scannersReal-Time Signal Tracking with Entry Level - Newser
Using flow based indicators on TransCode Therapeutics Inc.Technical Trend Forecast for Investors - Newser
Should you hold or exit TransCode Therapeutics Inc. nowMinimal Risk Growth Investment Opportunity Analysis - Newser
Real time alert setup for TransCode Therapeutics Inc. performanceVolume Spike Detection for Early Breakouts - Newser
Why TransCode Therapeutics Inc. stock attracts strong analyst attentionValue Investing Picks With Stability Outlined - metal.it
What’s next for TransCode Therapeutics Inc. stock priceStrong Buy With Technical Confidence Supported - metal.it
Is TransCode Therapeutics Inc. Stock a Good Fit for Conservative InvestorsFree Alpha Focused Technical Trade Signals - Newser
TransCode Therapeutics Inc. stock outlook for YEARFree High Growth Low Risk Stock Selection - Newser
How volatile is TransCode Therapeutics Inc. stock compared to the marketMarket Forecast Review For 2025 - jammulinksnews.com
How does TransCode Therapeutics Inc. generate profit in a changing economyMassive portfolio appreciation - jammulinksnews.com
What are analysts’ price targets for TransCode Therapeutics Inc. in the next 12 monthsRapid growth trajectories - jammulinksnews.com
Does TransCode Therapeutics Inc. stock perform well during market downturns - jammulinksnews.com
How does TransCode Therapeutics Inc. compare to its industry peersBuild a portfolio that stands the test of time - jammulinksnews.com
DSGR stock prediction for this week Free Trade Scanner With Buy Zone Alerts - Newser
Candlestick signals on TransCode Therapeutics Inc. stock today Long-Term Investment Strategy Summary Guide - Newser
When is TransCode Therapeutics Inc. stock expected to show significant growthMaximize your gains with professional insights - jammulinksnews.com
What makes TransCode Therapeutics Inc. stock price move sharplyGet timely alerts on market opportunities - jammulinksnews.com
How many analysts rate TransCode Therapeutics Inc. as a “Buy”Discover undervalued stocks before they soar - jammulinksnews.com
What institutional investors are buying TransCode Therapeutics Inc. stockMaster stock selection with insider knowledge - jammulinksnews.com
What is the dividend policy of TransCode Therapeutics Inc. stockRealize exceptional returns through smart trading - jammulinksnews.com
TransCode Therapeutics Inc. Company Revenue and Profit Trends: A Deep DiveExpert Trading Flow - Newser
Sectors Driving Future Growth for WASH Stock200 Percent Gain Alert - Newser
Why SCPH stock attracts strong analyst attentionHigh Accuracy Alerts - metal.it
TransCode Therapeutics Inc. Stock Analysis and ForecastConsistent triple returns - PrintWeekIndia
What drives TransCode Therapeutics Inc. stock priceRobust financial gains - Autocar Professional
Is TransCode Therapeutics Inc. a good long term investmentExtraordinary earning power - PrintWeekIndia
What analysts say about TransCode Therapeutics Inc. stockFree Trend-Following Techniques - Autocar Professional
RNAZ’s Stock Market Odyssey: A Year of Growth, Decline, and Resilience - investchronicle.com
Transcode Therapeutics Inc Stock (RNAZ) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):